How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

632 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Cervical Cancer: ESMO Clinical Practice Guidelines

Cervical Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † C. Marth 1 , F. Landoni 2 , S. Mahner 3 , M. McCormack 4 , A. Gonzalez-Martin 5 & N. Colombo 2 , on behalf of the ESMO Guidelines Committee * 1 Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; 2 Department of Gynecologic Oncology, European Institute of Oncology, Milan, Italy; 3 (...) Department of Gynecology and Obstetrics, University of Munich, Munich, Germany; 4 Department of Oncology, University College Hospital, London, UK; 5 Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain *Correspondence to: ESMO Guidelines Committee, ESMO Head Of?ce, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: January 2008, last update May 2017. This publication supersedes the previously published

2017 European Society for Medical Oncology

122. An update to the Greig Health Record: Preventive health care visits for children and adolescents aged 6 to 17 years ? Technical report

a helpful statement for guidance in such cases. Template use In the , checklist templates are divided into three age ranges: , and years (inclusive). Section headings include: Weight, Height and BMI, Psychosocial history and Development, Nutrition, Education & Advice, Specific Concerns, Examination, Assessment, Immunization, and Medications . The checklist tables are divided arbitrarily into early, middle and late age groupings, but it is important to remember that children develop at different rates (...) -impaired driving. The CRAFFT screening questionnaire is highly sensitive for alcohol and drug problems in adolescents and young adults under 21 years of age and is included in the Greig Health Record. - Note that prescription medications such as opioids and stimulants may also be abused. Caffeine Physicians may not be accustomed to asking children and youth about caffeine use and the use of energy drinks. The consumption of caffeinated energy drinks is problematic in youth who commonly combine them

2016 Canadian Paediatric Society

123. Gardasil 9 - human papillomavirus 9-valent vaccine (recombinant, adsorbed)

and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types ? Genital warts (Condyloma acuminata) caused by specific HPV types. Pharmaceutical form(s): Suspension for injection Per 0.5 ml dose: Human Papillomavirus Type 6 L1 EMA/CHMP/76591/2015 Page 3/128 Strength(s): protein 30 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 60 micrograms Human Papillomavirus Type 18 L1 protein 40 micrograms Human Papillomavirus Type 31 L1 (...) on the procedure 6 2. Scientific discussion 8 2.1. Problem statement 8 2.2. About the product 9 2.2.1. Introduction 10 2.2.2. Active Substance 10 2.2.3. Finished Medicinal Product 16 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 20 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 22 2.2.6. Recommendation(s) for future quality development 22 2.2.7. Introduction 22 2.2.8. Pharmacology 23 2.2.9. Pharmacokinetics 24 2.2.10. Toxicology 24 2.2.11. Ecotoxicity

2015 European Medicines Agency - EPARs

124. A decision aid for women with a mildly abnormal Pap smear

Pap smear? x An ‘abnormal’ Pap smear result means that some of the cells of the cervix have been found to differ in some way from the normal cells. x The abnormal cell changes ARE NOT cancer. x There are different categories of abnormal cells from mild to moderate to severe. These are described in the table below. x It is important to remember that medical care for abnormal cells of the cervix (including all types described below) is very effective. Abnormal cell type Description Other terms (...) stands for cervical intraepithelial neoplasia. It is the medical term for cervical cell changes. The highlighted areas show the categories that are relevant to you now. 29 STEP 1 How important are the advantages of HPV testing & usual care to you? ADVANTAGES OF HPV TESTING ADVANTAGES OF USUAL CARE I may test negative for HPV and not need another Pap smear for 1 year Not at all ? O ? O ? O ? Extremely Important Important I have a lower chance of having a colposcopy & biopsy Not at all ? O ? O ? O

2015 SickKids Supportive Care Guidelines

125. Childhood Cancer Genomics (PDQ®): Health Professional Version

Childhood Cancer Genomics (PDQ®): Health Professional Version Childhood Cancer Genomics (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD (...) histologies that have distinctive biological features and distinctive clinical characteristics (particularly in terms of prognosis). In some instances, identification of these subtypes has resulted in early clinical translation as exemplified by the WNT subgroup of medulloblastoma. Because of its excellent outcome, the WNT subgroup will be studied separately in future medulloblastoma clinical trials so that reductions in therapy can be evaluated with the goal of maintaining favorable outcome while

2018 PDQ - NCI's Comprehensive Cancer Database

126. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version Unusual Cancers of Childhood Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries (...) , although the overall incidence of childhood cancer has been slowly increasing since 1975.[ ] Referral to medical centers with multidisciplinary teams of cancer specialists experienced in treating cancers that occur in childhood and adolescence should be considered for children and adolescents with cancer. This multidisciplinary team approach incorporates the skills of the primary care physician, pediatric surgeons, radiation oncologists, pediatric medical oncologists/hematologists, rehabilitation

2018 PDQ - NCI's Comprehensive Cancer Database

127. Childhood Laryngeal Tumors Treatment (PDQ®): Health Professional Version

Childhood Laryngeal Tumors Treatment (PDQ®): Health Professional Version Childhood Laryngeal Tumors Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet (...) tumor is subglottic hemangioma.[ ] Malignant tumors, which are especially rare, may be associated with benign tumors such as polyps and papillomas.[ , ] Clinical Presentation These tumors may present with the following: Hoarseness. Difficulty swallowing. Enlargement of the lymph nodes of the neck. Treatment of Childhood Laryngeal Cancer Rhabdomyosarcoma is the most common pediatric malignant tumor of the larynx and is treated with chemotherapy and radiation therapy.[ ] (Refer to the PDQ summary

2018 PDQ - NCI's Comprehensive Cancer Database

128. HIV infection and AIDS

. Information on . Information on . Management for if needed. Management for HIV-related problems if needed. See the for more information. Be aware of potential problems with drug interactions — (ART) can have serious interactions with many other drugs, dietary substances, herbal remedies, and recreational drugs. To minimize the risk of drug interactions: Take a detailed medication history including over-the-counter and recreational drugs, and complementary therapy/herbal remedies. Do not discontinue (...) -threatening and require urgent admission or referral to secondary care. Management of HIV is complex and is carried out by specialist HIV services in secondary care. Antiretroviral therapy (ART) is initiated and monitored in secondary care but it is important to be aware of the potential for serious and life-threatening adverse effects that may present in primary care. ART can also have serious or life-threatening interactions with many drugs commonly prescribed in primary care — check before prescribing

2018 NICE Clinical Knowledge Summaries

129. Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus

medications select for resistant mutations when used as monotherapy; therefore, antiretroviral therapy uses combinations of three or more drugs. Strict adherence to the dose regimens is critical to sustain HIV suppression, to reduce the risk of drug resistance, to improve overall quality of life and survival, and to decrease the risk of HIV transmission (6). Because nonadherence to antiretroviral therapy may lead to the emergence of drug resistance and loss of future treatment options, all health care (...) providers, including gynecologists, should ask about and encourage adherence to treatment medications. Current treatment recommendations for women and adolescents with HIV can be found at . Clinical Considerations and Recommendations What are the special considerations for antiretroviral drug therapy in nonpregnant women infected with HIV? There currently are more than 20 U.S. Food and Drug Administration-approved antiretroviral agents from six medication classes that can be used to formulate

2016 American College of Obstetricians and Gynecologists

130. Management of Vulvar Intraepithelial Neoplasia

). Medical Therapy Randomized controlled trials have shown that the application of topical imiquimod 5% is effective for the treatment of vulvar HSIL (VIN usual type) ( , ), although it is not approved by the U.S. Food and Drug Administration for this purpose. Published regimens include three times weekly application to affected areas for 12–20 weeks, with colposcopic assessment at 4–6-week intervals during treatment. Residual lesions require surgical treatment. Erythema and vulvar pain may limit use (...) genital warts and in women of all ages with suspected condyloma in whom topical therapies have failed. Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL. When occult invasion is not a concern, vulvar HSIL (VIN usual type) can be treated with excision, laser ablation, or topical imiquimod (off-label use). Women with vulvar HSIL (VIN

2016 American College of Obstetricians and Gynecologists

131. WHO guidelines for the treatment of Treponema pallidum (syphilis)

.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int (...) guidelines for the treatment of T. pallidum (syphilis) 18 Adaptation, implementation and monitoring 18 Identifying and procuring STI medicines 19 4. Recommendations for treatment of syphilis 20 4.1 Early syphilis 20 Recommendation 1 20 Recommendation 2 20 Recommendation 3 21 Recommendation 4 21 4.2 Late syphilis 22 Recommendation 5 22 Recommendation 6 22 Recommendation 7 22 Recommendation 8 22WHO GUIDELINES FOR THE TREATMENT OF TREPONEMA PALLIDUM (SYPHILIS) ii 4.3 Congenital syphilis 23 Recommendation 9

2016 World Health Organisation Guidelines

132. WHO guidelines for the treatment of Neisseria gonorrhoeae

WHO guidelines for the treatment of Neisseria gonorrhoeae WHO GUIDELINES FOR THE Treatment of Neisseria gonorrhoeae WHO GUIDELINES FOR THE Treatment of Neisseria gonorrhoeae WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Neisseria gonorrhoeae. Contents: Web annex D: Evidence profiles and evidence-to-decision framework -- Web annex E: Systematic reviews -- Web annex F: Summary of conflicts of interest 1.Neisseria gonorrhoeae - drug therapy. 2.Gonorrhea - drug (...) therapy. 3.Drug Resistance, Microbial. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154969 1 (NLM classification: WC 150) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce

2016 World Health Organisation Guidelines

133. WHO guidelines for the treatment of Genital Herpes Simplex Virus

not be possible during the course of treatment and symptoms of the first clinical episode may be prolonged, therapy is provided for 10 days. Although the benefits of the medicines are probably similar, the costs of valaciclovir and famciclovir are higher than aciclovir, and therefore aciclovir is preferred. The choice of medicine may also depend on compliance considerations. This recommendation also applies to people living with HIV, people who are immunocompromised, people with a severe episode and pregnant (...) will likely choose suppressive therapy over episodic therapy. To determine frequency or severity, episodes can be monitored for the first few months. Although the benefits of the medicines may be similar, the costs of valaciclovir and famciclovir are higher than aciclovir, and therefore aciclovir is preferred. The choice of medicine may also depend on compliance considerations. Conditional recommendation, low quality evidence 5 STI EPIDEMIOLOGY AND BURDEN Sexually transmitted infections (STIs) are a major

2016 World Health Organisation Guidelines

134. Triumeq - abacavir sulfate / dolutegravir sodium / lamivudine

that there are no significant changes for any of the evaluated parameters established for the stability studies. All stability studies results indicate that the active substance is stable at controlled room temperature. The results justify the proposed retest period in the proposed container. 2.2.1. Finished Medicinal Product Description of the product and Pharmaceutical development The aim of the drug development was to develop a pharmaceutical form combining the currently approved doses of dolutegravir, abacavir (...) quality attributes identified were description, identity, content, uniformity of content, drug-related impurities and dissolution. The development of the medicinal product was based on prior knowledge of the fixed-dose combination abacavir/lamivudine tablets and the recently developed monocomponent dolutegravir 50 mg tablets. The pharmaceutical formulation and manufacturing development have been evaluated through the use of risk assessment and design of experiments to identify the critical product

2014 European Medicines Agency - EPARs

135. Nurse led immunisation of school aged children

and ethics for nurses and midwives, London: NMC. Available at www.nmc-uk.org Nursing and Midwifery Council (2008b) Standards for medicines management, London: NMC. Available at www.nmc-uk.org RCN online guidance www.rcn.org.uk/support/rcn_direct_ online_advice/a-z2/patient_group_directions_pgds/pgds RCN online advice www.rcn.org.uk/support/rcn_direct_ online_advice/a-z2/consent You will need your membership number to access these RCN online advice guides. References British Medical Association (2010 (...) direction (PGD) for: GARDASIL® Human papilloma virus vaccine [Types 6, 11, 16, 18] (recombinant, adsorbed) Vaccination is not a substitute for routine cervical screening 2. Drug details Name, form and strength of medicine GARDASIL® Human papilloma virus vaccine [Types 6, 11, 16, 18] (recombinant, adsorbed) Legal classification POM – Prescription only medicine Dose 0.5 mL dose supplied in a pre-filled syringe should be used for each injection in accordance with the recommended schedule. Route/method

2014 Royal College of Nursing

136. Comprehensive cervical cancer control

its use. Printed in 1.Uterine Cervical Neoplasms - diagnosis. 2.Uterine Cervical Neoplasms - prevention and control. 3.Uterine Cervical Neoplasms – therapy. 4.Guideline. I.World Health Organization. WHO Library Cataloguing-in-Publication Data Comprehensive cervical cancer control: a guide to essential practice – 2 nd ediii Acknowledgements The World Health Organization (WHO) would like to thank the members of the Guideline Development Group for their constant availability and hard work (...) , Switzerland Linda O’Neal Eckert Department of Obstetrics and Gynecology University of Washington Seattle, WA, USA Andreas Ullrich Management of Noncommunicable Diseases WHO Headquarters Geneva, Switzerland Paul Bloem Immunization, Vaccines and Biologicals WHO Headquarters Geneva, Switzerlandv Contents Acknowledgements iii Acronyms and abbreviations 1 Compilation of key points 3 Preface 8 Introduction 11 About the guide 11 Levels of the health-care system 18 Essential reading 19 Chapter 1. Background 23

2015 World Health Organisation Guidelines

137. Common conditions and diseases in HIV-positive men who have sex with men

to antiretroviral adherence. Serious drug interactions can also result from concurrent use of drugs and antiretroviral medications.(23-29) Differences in prevalence also exist in the area of mental health: ? Mental health issues experienced by HIV-positive men who have sex with men are similar to the types of issues reported in the general population. (30) Common mental health disorders associated with HIV include: adjustment disorders, mood disorders, anxiety disorders, substance-related disorders, and HIV (...) than HIV-positive men who have sex with men.(21) Matching of STI and AIDS databases in San Francisco has shown that people on highly active antiretroviral therapy (HAART) are more likely to develop another STI.(16) However, the differences in infection rates between HIV-positive and negative men who have sex with men may be due in part to a detection bias: HIV-positive men who have sex with men are generally under regular medical care so they are more likely to be screened for STIs. (15) Most STIs

2014 Ontario HIV Treatment Network

138. Management of Hepatitis C

treated with combination drug therapy (pegylated interferon alfa and ribavirin) with sustained viral response (SVR) rates in 50-80% of patients. Although there are existing guidelines for the selection of patients for treatment 4-7 there are no national guidelines for screening, testing, diagnosis, service configuration, care during treatment or post-treatment follow up in adults or children. 1.1.1 UPDATING THE EVIDENCE This guideline updates SIGN 92: Management of hepatitis C to reflect the most (...) by appropriate evidence and experience. 8 “Prescribing medicines outside the conditions of their marketing authorisation alters (and probably increases) the prescribers’ professional responsibility and potential liability” . 8| 3 Management of hepatitis C The General Medical Council (GMC) recommends that when prescribing a medicine off-label, doctors should: y be satisfied that such use would better serve the patient’s needs than an authorised alternative (if one exists) y be satisfied

2013 SIGN

139. Effect of Immunomodulatory Supplements Based on Echinacea Angustifolia and Echinacea Purpurea on the Posttreatment Relapse Incidence of Genital Condylomatosis: A Prospective Randomized Study. Full Text available with Trip Pro

infection causes condylomatosis relapse; in order to reduce the relapse risk an induction of a protective immune response seems to be essential to allow rapid viral clearance from genital areas surrounding lesion and treatment zones. Echinacea promotes this process. EP and EA dry root extracts seem to be a valid adjuvant therapy in reducing relapse incidence of lesions in patients treated for genital condylomatosis. (...) Effect of Immunomodulatory Supplements Based on Echinacea Angustifolia and Echinacea Purpurea on the Posttreatment Relapse Incidence of Genital Condylomatosis: A Prospective Randomized Study. Introduction. HPV infection is a highly infectious disease; about 65% of partners of individuals with genital warts will develop genital condylomatosis. Only in 20-30% it regresses spontaneously and relapse rates range deeply (9-80%). Echinacea extracts possess antiviral and immunomodulator activities

2019 BioMed research international Controlled trial quality: uncertain

140. Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: No previous treatment for anogenital warts Negative serology for HB and HIV. Signed informed consent. Exclusion Criteria: Pregnancy Treatment with steroids, immune-suppressors, immune-modulators or local or systemic antiviral drugs. Hypersensitivity to Glizigen or Viusid: Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research (...) -Viudid in the Treatment of External Anogenital Warts in Children and Adolescents. Study Start Date : December 2010 Actual Primary Completion Date : September 2011 Actual Study Completion Date : September 2011 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Glizigen + Viusid Dietary Supplement: Glizigen + Viusid Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>